Pitfalls of treating chronic myeloid leukaemia with dasatinib – pulmonary arterial hypertension as a rare complication
Authors:
P. Čičátková; A. Kvetková; T. Horňák; L. Semerád; D. Žáčková
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
Published in:
Transfuze Hematol. dnes,27, 2021, No. 2, p. 166-171.
Category:
Case Report
doi:
https://doi.org/10.48095/cctahd2021166
Overview
Dasatinib is a potent tyrosine kinase inhibitor of not only Bcr-Abl1, but also of the Src kinase family, c-kit and PDGFR-â. This “off-target” effect is the probable cause of pleural effusions, which complicate dasatinib therapy in about one third of patients. The following case report describes a chronic myeloid leukaemia patient with not only recurrent pleural effusions but also pulmonary arterial hypertension as a serious adverse event leading to dasatinib discontinuation.
Keywords:
chronic myeloid leukaemia – dasatinib – pleural effusions – pulmonary arterial hypertension
Sources
1. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376(10):917–927.
2. Shah NP, Rouselot P, Schiffer Ch, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia patient: 7-years follow-up of study CA 180-034. Am J Hematol. 2016, 91(9):869–874.
3. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effecctive in patients with Philaadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540–3546.
4. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Näive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
5. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054.
6. Zackova D, Klamova H, Belohlavkova P, et al. Dasatinib treatment long-term results among imatinib-resistant/ intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. Leuk Lymphoma. 2021;62(1):194–202.
7. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/ Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658–6661.
8. O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistent Abl kinase domain mutants. Cancer Res. 2005;65:4500–4505.
9. Bergeon A, Rea D. Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia. Am J Respir Crit Care Med. 2007;176:814–818.
10. Luton F, Verges M, Vaerman JP, et al. The SRC family protein tyosine kinase p62yes contols polymeric IgA transcytosis in vivo. Mol Cell. 1999;4:627–632.
11. Quintás-Cardama A, Kantarjian H, O‘brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908–3914.
12. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141:745–747.
13. Hellstom M, Kalen M, Lindahl P, et al. Role of PDGF-B and PDGFR- in recruitment of vascula smooth muscle cells and pericytes during embryonic blood vesel formation in the mouse. Development. 1999;126:3047–3055.
14. La Rosée P, Martiat P, Leitner A, et al. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. 2013;92(10):1345–1350.
15. Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as fontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126:67–75.
16. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–1671.
17. Dodson MW, Brown LM, Elliot ChG. Pulmonary arterial hypertension. Heart Fail Clin. 2018;14(3):255–269.
18. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–1820.
19. Ryan JJ, Thenappan T, Luo N, et al. The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulm Circ. 2012;2(1):107–121.
20. Čičátková P, Žáčková D. Vysazování inhibitorů tyrozinkináz u pacientů s chronickou myeloidní leukemií ve studiích a klinické praxi. Transfuze Hematol Dnes. 2020;26(4):281–293.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2021 Issue 2
Most read in this issue
- Transfusion related acute lung injury (TRALI) prevention – selection of donors for producing plasma designated for clinical use
- A peripherally inserted central catheter is a safe means of ensuring long-term central venous access in patients with acute leukaemia – a single centre experience
- Mucormycosis – review of literature and case report
- Changes in the immune system of untreated patients with chronic lymphocytic leukaemia – part 1: adaptive immunity